BS_4Z2F4P9N
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 0.863
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.596
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.568
- IL6_JAK_STAT3_SIGNALING+0.558
- COAGULATION+0.475
- INFLAMMATORY_RESPONSE+0.458
- ALLOGRAFT_REJECTION+0.449
- INTERFERON_GAMMA_RESPONSE+0.449
- INTERFERON_ALPHA_RESPONSE+0.442
- COMPLEMENT+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
Top 10 suppressed
- SPERMATOGENESIS-0.297
- PANCREAS_BETA_CELLS-0.282
- E2F_TARGETS-0.205
- G2M_CHECKPOINT-0.201
- HEME_METABOLISM-0.131
- MITOTIC_SPINDLE-0.067
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.041
- PEROXISOME-0.030
- BILE_ACID_METABOLISM-0.029
- KRAS_SIGNALING_DN-0.008
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_77CDMEY4 | Ganglioglioma | — | 0.920 |
| 2 | BS_06AMMCXR | low-grade glioma | — | 0.916 |
| 3 | BS_DEHJF4C7 | low-grade glioma | — | 0.913 |
| 4 | BS_EN2VK7NY | low-grade glioma | — | 0.908 |
| 5 | BS_N1E0H8YQ | low-grade glioma | — | 0.899 |
| 6 | BS_4T0HPZDC | EPN | Posterior Fossa EPN | 0.898 |
| 7 | BS_2YCJV2VV | low-grade glioma | — | 0.897 |
| 8 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.895 |
| 9 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.888 |
| 10 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.596 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.568 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.558 | Inavolisib | — uncovered |
| COAGULATION | 0.475 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.458 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.449 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.449 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.442 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.417 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.414 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.401 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.384 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.383 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.369 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.364 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.358 | Inavolisib | — uncovered |
| APOPTOSIS | 0.337 | Idelalisib | — uncovered |